Anti-TGF-β/PD-L1 bispecific antibody YM101 is superior to anti-TGF-β and anti-PD-L1 monotherapies, increasing the numbers of tumor infiltrating lymphocytes and dendritic cells, elevating the ratio of M1/M2, and enhancing cytokine production in T cells (176). The gene discussed is TGFB1; the disease is neoplasm.